Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis

Gastroenterology

Volumn 123, Issue 4, 2002, Pages 1006-1012

  Laine, Loren ^a   Bombardier, Claire ^b   Hawkey, Christopher J ^c   Davis, Barry ^d   Shapiro, Deborah ^e   Brett, Christopher ^e   Reicin, Alise ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF TEXAS   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CIMETIDINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SUCRALFATE;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOMACH OBSTRUCTION; UPPER GASTROINTESTINAL TRACT;

EID: 0036789104     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36013     Document Type: Article

References (23)

1. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772.
2. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal antiinflammatory drugs and complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-130.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Bosi Ferraz M, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
4. Tukey J. Use of many covariates in clinical trials. Int Stat Rev 1991;59:123-137.
5. Shapiro DR, Cook TJ. Analysis of long term adverse experience data using the weibull model. Drug Info J 1994;28:541-552.
6. Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, Geis GS. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double- blind, placebo-controlled trial. Ann Intern Med 1995;123:241-249.
7. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787-796.
8. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-740.
9. Kurata JH, Abbey DE. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalizations. J Clin Gastroenterol 1990; 12:260-266.
10. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer in elderly persons. Ann Intern Med 1991;114:257-263.
11. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 1996;28:204-210.
12. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. J Rheumatol 1998; 25(Suppl 51):8-16.
13. Singh G, Ramey DR, Morfeld D, Shie H, Hatoum HT, Fries JF. Gastrointestinal traact complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 1996;156:1530-1536.
14. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28:527-532.
15. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case control study. Gut 1991;32:730-734.
16. Weil J, Langman MJS, Wainwright P, Lawson DH, Rawlins M, Logan RFA, Brown TP, Vessey MP, Murphy M, Colin-Jones DG. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
17. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated: a meta-analsyis of rigorously designed trials. Am J Gastroenterol 1998;93:1409-1415.
18. Gudjonsson B, Spiro HM. Response to placebo in ulcer disease. Am J Med 1978;65:399-402.
19. Laine L. Approaches to NSAID use in the high-risk patient. Gastroenterology 2001;120:594-606.
20. Kumana CR, Cheung BM, Lauder IJ. Gauging the impact of statins using number needed to treat. JAMA 1999;282:1899-1901.
21. MacDonald TM, Morant SV, Robinson GC, Shield MJ, McGilchrist MM, Murray FE, McDevitt DG. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333-1337.
22. Hallas J, Lauritsen J, Dalsgard Villadsen H, Freng Gram L. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol 1995;30:438-444.
23. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141:539-545.